BIOSECURE readiness support for Chinese life-sciences companies facing U.S. customer, supply-chain, or federal procurement questions. We organize ownership and vendor facts, contract exposure, policy developments, and counsel-reviewed communications. Enacted law, implementation requirements, customer policy, and individual contract terms are checked separately; qualified counsel determines legal applicability.
CFIUS communications and evidence coordination for transaction teams preparing for review or a possible National Security Agreement. We organize ownership, governance, technology, data-access, and stakeholder facts around counsel’s strategy. Qualified counsel leads jurisdictional analysis, filings, legal negotiations, and interpretations of mitigation obligations; SIC Group supports the operating and communications record.
Public affairs and market-access risk preparation for Chinese life-sciences companies entering the United States. We distinguish FDA scientific review, regulatory submissions, commercial access, and policy exposure, then organize executive materials and stakeholder questions. Regulatory counsel and scientific specialists own the submission and evidence; political outreach cannot replace FDA’s independent evaluation.
Policy and communications preparation for investors, biotech companies, and defense supply chains facing COINS outbound-investment questions or section 1260H concerns. We separate investment rules, list status, procurement clauses, and lobbying restrictions, then build a dated evidence and issue matrix. Counsel determines each rule’s applicability, prohibitions, notification duties, and engagement boundaries.